Cancer Genetics and Epigenetics 2024, Vol.12, No.2, 97-105 http://medscipublisher.com/index.php/cge 99 detection and management of prostate cancer, potentially reducing unnecessary biopsies and overtreatment (Cucchiara et al., 2018; Nevo et al., 2020). 2.3 Ethnic variability in genetic markers Ethnic variability plays a significant role in the prevalence and impact of genetic markers for prostate cancer. African American men, for instance, are at a higher risk of developing prostate cancer at younger ages compared to other ethnic groups. The rs6983561 genotype has been found to be significantly associated with earlier time to prostate cancer diagnosis among African American men, highlighting the importance of considering ethnic differences in genetic screening (Hughes et al., 2012). Furthermore, studies have shown that the frequency of certain genetic markers and their associated risks can vary among different ethnic groups, necessitating tailored screening and risk assessment strategies (Costa et al., 2007). Understanding these ethnic variations is crucial for developing personalized approaches to prostate cancer screening and treatment. 3 Advances in Genetic Screening Technologies 3.1 Next-generation sequencing (NGS) Next-Generation Sequencing (NGS) has revolutionized the field of genetic screening by enabling the rapid and cost-effective sequencing of large amounts of DNA. This technology has significantly improved the accuracy and depth of genetic analysis, making it a powerful tool in the early screening of prostate cancer. NGS can be applied to both tissue biopsies and liquid biopsies, allowing for comprehensive genomic profiling of prostate cancer. For instance, NGS has been successfully used to detect mutations in formalin-fixed prostate cancer biopsies, identifying alterations in multiple cancer-related genes, which can inform clinical decision-making and treatment strategies (Beltran et al., 2013; Manson-Bahr et al., 2015). Additionally, the European Society for Medical Oncology (ESMO) recommends the routine use of NGS in advanced prostate cancers to identify actionable genetic alterations that can guide personalized therapy (Mosele et al., 2020). 3.2 Genome-wide association studies (GWAS) Genome-Wide Association Studies (GWAS) have identified numerous genetic polymorphisms and inherited variants associated with prostate cancer susceptibility. These studies have enhanced our understanding of the genetic basis of prostate cancer and have led to the development of new genomic tools for risk assessment and disease management. For example, GWAS have identified specific genetic markers that can discriminate between clinically insignificant and aggressive tumors, aiding in the stratification of patients and the selection of appropriate therapies (Choudhury et al., 2012). Moreover, commercial tools such as Decipher, Oncotype DX, and Prolaris, which are based on GWAS findings, have improved risk stratification and prognostication in prostate cancer (Cucchiara et al., 2018). 3.3 Liquid biopsy techniques Liquid biopsy techniques have emerged as a minimally invasive alternative to traditional tissue biopsies, offering a practical approach to monitor tumor dynamics over time. These techniques involve the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs) in blood samples. Liquid biopsies can provide real-time insights into tumor progression, treatment response, and resistance mechanisms. For instance, NGS applied to ctDNA can detect low-frequency mutations at early stages of cancer, facilitating early diagnosis and monitoring (Chen and Zhao, 2019). Additionally, liquid biopsies have shown promise in identifying prognostic and predictive biomarkers in advanced prostate cancer, such as androgen receptor (AR) variants and DNA repair gene mutations, which can guide targeted therapies (Oellerich et al., 2017; Morrison and Goldkorn, 2018). However, the implementation of liquid biopsy techniques in clinical practice requires standardization and validation to ensure their reliability and clinical utility (Casanova-Salas et al., 2021). Advances in genetic screening technologies, including NGS, GWAS, and liquid biopsy techniques, have significantly enhanced the early detection and management of prostate cancer. These technologies offer new opportunities for personalized medicine, enabling more accurate risk assessment, early diagnosis, and tailored treatment strategies. However, further research and validation are needed to fully integrate these tools into routine clinical practice.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==